TITLE

General considerations

PUB. DATE
September 2004
SOURCE
WHO Technical Report Series;2004, Issue 927, p66
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on polysaccharide vaccines for infections caused by Streptococcus pneumoniae, which are responsible for substantial morbidity and mortality, commonly on children and the elderly. Pneumociccus are classified based on chemical and serological distinct capsular polysaccharides. Polysaccharide vaccines are efficacious in children about 2 year of age but are not effective in younger children, while polysaccharide-protein conjugates have been demonstrated to be high in immunogenic in infants and to stimulate T-cell dependent immunity.
ACCESSION #
19839153

 

Related Articles

  • Pneumococcal Immunization: From Policy to Practice. Schwartz, Benjamin; Breiman, Robert F. // JAMA: Journal of the American Medical Association;9/5/90, Vol. 264 Issue 9, p1154 

    Editorial. Deals with the low utilization of pneumococcal vaccines targeted for adults in the U.S. Factors behind the lack of use of pneumococcal vaccines; Strategies that can be adopted to increase utilization of pneumococcal vaccines; Cost benefits of immunization.

  • New children's vaccines, new direction. Kassianos, George // GP: General Practitioner;1/12/2007, p30 

    The article focuses on issues related to the introduction of routine immunization of infants against pneumococcal disease in Great Britain. The new immunization schedule was announced on June 12, 2006. One of the problems of introducing a new vaccine is how to fit another vaccine into the...

  • Prevenar joins schedule in June. Reid, Stewart // New Zealand Doctor;5/7/2008, p17 

    The article focuses on the use of Prevenar as vaccine. According to the author, starting June 1, 2008 heptavalent conjugate pneumococcal vaccine Prevenar will be part of the New Zealand routine immunization schedule. The immunization will have a four-dose schedule with doses at six weeks, three,...

  • Management of pneumococcal vaccination. Burns, Jackie // Primary Health Care;May2004, Vol. 14 Issue 4, p17 

    Gives advice on the management of pneumococcal vaccination. Recommendations for pneumococcal vaccination; Diseases caused by pneumococcal infection in older people; Identifying candidates for pneumococcal vaccination; Contraindications to pneumococcal polysaccharide vaccine.

  • Potential Impact of Conjugate Pneumococcal Vaccines on Pediatric Pneumococcal Diseases. O'Brien, Katherine L.; Santosham, Mathuram // American Journal of Epidemiology;Apr2004, Vol. 159 Issue 7, p634 

    Children younger than age 2 years have the highest rates of invasive pneumococcal disease and play an important role in its transmission. In the United States, seven pneumococcal serotypes cause approximately 80% of invasive disease and represent approximately 60% of middle-ear isolates in...

  • Vaccination against pneumococcus in West Africa: perspectives and prospects. Donkor, Eric S.; Dayie, Nicholas T. K. D.; Badoe, Ebenezer V. // International Journal of General Medicine;2013, Vol. 6, p757 

    Background: Pneumococcal vaccination has become obligatory due to the enormous burden of pneumococcal diseases. Quite recently, pneumococcal conjugate vaccines have been developed, and have been shown to be superior to the previous polyvalent polysaccharide vaccine of the organism. Pneumococcal...

  • Editorial Response: Predicting Protection Against Encapsulated Pathogens. Janoff, Edward N.; Rubins, Jeffrey B. // Clinical Infectious Diseases;8/1/1999, Vol. 29 Issue 2, p289 

    Comments on the article of Sandra Romero-Steiner et al. in the August 1999 issue of 'Clinical Infectious Diseases' on the comparison of levels of capsule-specific immunoglobulin G (IgG) after pneumococcal vaccination in elderly and younger patients. Parameters which determine antibody avidity;...

  • Differential Effects of Pneumococcal Vaccines against Serotypes 6A and 6C. Park, In H.; Moore, Matthew R.; Treanor, John J.; Pelton, Stephen I.; Pilishvili, Tamara; Beall, Bernard; Shelly, Mark A.; Mahon, Barbara E.; Nahm, Moon H. // Journal of Infectious Diseases;12/15/2008, Vol. 198 Issue 12, p1818 

    Background. Because classic pneumococcal serotyping methods cannot distinguish between serotypes 6A and 6C, the effects of pneumococcal vaccines against serotype 6C are unknown. Pneumococcal vaccines contain serotype 6B but not serotypes 6A and 6C. Methods. We used a phagocytic killing assay to...

  • WHAT'S NEW IN DRUGS.  // RN;Dec79, Vol. 42 Issue 12, p101 

    Presents information on a polyvalent pneumococcal vaccine for the immunization of patients against pneumococci infections. Patients qualified for the vaccine; Infections prevented by the vaccine; Contraindications.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics